The 3 Highest-Yielding Dividend Kings in April

The article highlights three Dividend Kings with high yields: Altria at 6.3%, Universal Corporation at 6.1%, and Kimberly-Clark at 5.2%. Altria faces declining cigarette demand in North America but offsets it with pricing power; Universal benefits from global tobacco exposure but has volatile commodity-like revenue; Kimberly-Clark is pursuing a growth-oriented transformation via its planned Kenvue acquisition, which brings integration risk. Overall, the piece is more an investor screening/commentary article than a catalyst-driven news event.

Analysis

The market is effectively pricing three different flavors of duration risk: MO is a slow-burn cash-flow story with secular volume decay masked by pricing power; UVV is a volatile commodity proxy with better geographic mix but less predictability; KMB is the only one with a credible multi-year re-rating path if the Kenvue deal closes and integration lands. The key second-order point is that high yield here is not “income safety” but compensation for business model fragility, so the better trade is not simply highest yield, but best asymmetry between payout support and operating optionality.

MO’s biggest vulnerability is not near-term dividend coverage, it is reinvestment optionality. If capital continues to be spent on adjacent nicotine formats with write-down risk, the dividend may remain intact while equity value erodes via repeated capital misallocation; that makes it a classic yield trap where the downside is slower but more durable than the headline yield suggests. UVV benefits if non-North American cigarette demand remains resilient, but because tobacco leaf is a commodity input, its earnings can lag volume recovery or be squeezed by inventory normalization, so the upside is more cyclical than structural.

KMB is the only name where leverage can be converted into strategic upside rather than just balance-sheet risk. If management executes, Kenvue can improve growth and mix, but the first 6-12 months after close are likely to be dominated by integration uncertainty and multiple compression, not synergy capture. The contrarian read is that the market may be underestimating how much of KMB’s current yield discount is tied to execution fear rather than balance-sheet stress; if rates drift lower over the next 12-18 months, a stable staple with a credible growth bridge could rerate faster than the market expects.

Key Decisions for Investors

• Avoid chasing MO for income alone; if long, size as a covered-yield trade only and use a 6-12 month horizon, because the main risk is persistent multiple compression rather than dividend cut.
• Consider a relative-value pair: long KMB / short PG into the Kenvue close over the next 3-9 months; KMB has more rerating torque if the deal works, while PG is the cleaner defensive compounder and should be less exposed to integration disappointment.
• For investors who want tobacco exposure, prefer UVV over MO on a 3-6 month basis as a hedge against North American cigarette volume erosion, but keep position size modest because commodity earnings can swing sharply quarter to quarter.
• Use options for MO downside protection rather than outright exit: buy 6-9 month puts or finance with covered calls, since the stock can stay elevated on yield demand even as fundamentals deteriorate.
• If rates start trending lower, add to KMB on weakness rather than strength; lower discount rates plus a successful acquisition narrative could make the current yield look less compelling but the total return profile materially better.